Refine by
Gastrointestinal Articles & Analysis
183 news found
Its selective inhibition mechanism reduces gastrointestinal bleed risk commonly associated with other NSAIDs. Celecoxib is used to manage symptoms of various arthritis forms and also for familial adenomatous polyposis (FAP) to prevent precancerous polyps in the colon. ...
Gastrointestinal (GI) and liver diseases are complex conditions that can greatly impact a person's quality of life. ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. With the rise of antibiotic-resistant bacteria posing a significant threat to global public health, Ace Therapeutics announces its new vaccine ...
Various types of mucormycosis include: · Rhinocerebral mucormycosis · Pulmonary mucormycosis · Gastrointestinal mucormycosis · Cutaneous mucormycosis · Disseminated mucormycosis “As with most environmental diseases, pathogen overexposure and a suppressed immune system increase your ...
One of the key advantages of microneedles is its ability to bypass the oral route, which can often be associated with issues like poor bioavailability and gastrointestinal side effects. By delivering drugs through the skin, microneedle offers a viable alternative that eliminates the need for injections while ensuring safe and effective drug delivery. ...
They can be used for the delivery of small molecule drugs, biologics, vaccines, and even nucleic acids. By bypassing the gastrointestinal tract and avoiding first-pass metabolism, microneedle-based drug delivery allows for higher bioavailability and improved therapeutic outcomes. ...
Types of mucormycosis listed by CDC include: · Rhinocerebral mucormycosis · Pulmonary mucormycosis · Gastrointestinal mucormycosis · Cutaneous mucormycosis · Disseminated mucormycosis To help lower the risk of developing mucormycosis, CDC recommends at-risk people avoid direct contact with ...
Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product line - Gastrointestinal API Intermediates, featuring the groundbreaking compounds Fexuprazan and Vonoprazan Intermediates. ...
These thin films are designed to dissolve rapidly in the mouth, delivering drugs directly into the bloodstream, bypassing the gastrointestinal tract. This technology not only offers convenience and ease of administration but also enhances drug bioavailability, making it an attractive option for patients. ...
This condition can lead to a range of discomforting symptoms, including headaches, gastrointestinal disturbances, and skin issues, especially when histamine-rich foods are consumed. ...
Types of mucormycosis listed by CDC include: · Rhinocerebral (sinus and brain) mucormycosis · Pulmonary (lung) mucormycosis · Gastrointestinal mucormycosis · Cutaneous (skin) mucormycosis · Disseminated mucormycosis “To help lower one’s chances of developing mucormycosis, CDC ...
For example, Bifidobacteria, Lactobacilli, etc., can synthesize a variety of vitamins necessary for human growth and development. The human gastrointestinal tract is symbiotic with structurally complex and abundant microbiota. ...
Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, ...
Suono Bio, a preclinical stage company, has developed breakthrough technology − the “SuonoCalmTM” system − designed to potentially enable ultra-rapid delivery of therapeutics across tissues, including the gastrointestinal (GI) tract. Preclinical studies have demonstrated that the ultrasound-based technology can deliver small molecules, proteins, and ...
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of ...
In addition, the partnership will bring together each organization’s strengths and lay the foundation for future innovation in gastrointestinal care as Iterative Health integrates additional AI solutions into Gastro Health’s practices. ...
” To learn more about Iterative Health’s plan to redefine the current approach to gastrointestinal care with AI, please visit iterative.health. About CB Insights CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. ...
” Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development — all at a scale unmatched by ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
Just to name a few: first, the solubility of APIs in the dosage form will be improved; second, the dissolved state of the API in the gastrointestinal tract can be maintained for a longer time; third, increased bioavailability excipients can even co-work with the digestion and absorption of physiological lipids in the body to promote the absorption of drugs. ...